Genentech is currently experiencing a supply shortage for Nutropin AQ® NuSpin in the United States. See the latest update on Nutropin (somatropin) supply here.
Nutropin GPS™ (Growing Patient Support) offers you and your patients assistance throughout treatment from a dedicated case manager. Following the decision to prescribe growth hormone therapy, GPS services include device and injection training, insurance process management, a nurse hotline, and ongoing patient access and support programs. Call 1‐866‐NUTROPIN (1‐866‐688‐7674) to get started.
Priority Review
Check if Nutropin AQ® is available on a patient’s formulary within one working day.
Nutropin® Co-pay Card Program
Help with out‐of‐pocket costs for qualified Nutropin AQ patients.
Electronic Patient Consent Form
Ask your patients to fill the Patient Consent Form online.
Priority Review
Check if Nutropin AQ® is available on a patient’s formulary within one working day.
Nutropin® Co-pay Card Program
Help with out‐of‐pocket costs for qualified Nutropin AQ patients.
Electronic Patient Consent Form
Ask your patients to fill the Patient Consent Form online.
Patient: My insurance covers Nutropin, but can I receive help with my co-pay?
Key Features of the Nutropin Co-pay Card Program
*Co-pay assistance is capped at $500 per month, however, outstanding co-pay expenses above the $500 monthly cap may be submitted (up to the $5,000 cap) directly to Nutropin GPS by the end of the calendar year.
If you have questions, talk to your healthcare providers’ office or call us at: 1-866-688-7674.
Patients can enroll in the Co-pay Card Program online.
For more information, review the co-pay brochure.
The Co-pay Program is valid ONLY for patients with commercial (private or non-governmental) insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medicine. Patients using Medicare, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DoD), TRICARE or any other federal or state government program (collectively, “Government Programs”) to pay for their Genentech medicine are not eligible. The Program is not valid for Genentech medicines that are eligible to be reimbursed in their entirety by private insurance plans or other programs.
Under the Program, the patient may pay a co-pay. The final amount owed by a patient may be as little as $0 for the Genentech medicine (see Program specific details). The total patient out-of-pocket cost is dependent on the patient’s health insurance plan. The Program assists with the cost of the Genentech medicine only. It does not assist with the cost of other medicines, procedures or office visit fees. After reaching the maximum annual Program benefit amount, the patient will be responsible for all remaining out-of-pocket expenses. The Program benefit amount cannot exceed the patient’s out-of-pocket expenses for the cost associated with the Genentech medicine. The maximum Program benefit will reset every January 1st. The Program is not health insurance or a benefit plan. The patient’s non-governmental insurance is the primary payer. The Program does not obligate the use of any specific medicine or provider. Patients receiving assistance from charitable free medicine programs (such as the Genentech Patient Foundation) or any other charitable organizations for the same expenses covered by the Program are not eligible. The Program benefit cannot be combined with any other rebate, free trial or a similar offer for the Genentech medicine. No party may seek reimbursement for all or any part of the benefit received through the Program.
The Program may be accepted by participating pharmacies, physicians’ offices or hospitals. Once a patient is enrolled, the Program will honor claims with a date of service that precedes the Program enrollment date up to 180 days. Claims must be submitted within 365 days from the date of service unless otherwise indicated. Use of the Program must be consistent with all relevant health insurance requirements. Participating patients, pharmacies, physicians’ offices and hospitals are responsible for reporting the receipt of all Program benefits as required by any insurer or by law. Programs benefits may not be sold, purchased, traded or offered for sale.
The patient or their guardian must be 18 years of age or older to receive Program assistance. The Program is only valid in the United States and U.S. Territories, is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. Eligible patients will be automatically re-enrolled in the Program on an annual basis. Eligible patients will be removed from the Program after 3 years of inactivity (e.g., no claims submitted in a 3-year timeframe). Program eligibility and automatic re- enrollment are contingent upon the patient’s ability to meet all requirements set forth by the Program. Healthcare providers may not advertise or otherwise use the Program as a means of promoting their services or Genentech medicines to patients. The Program is intended for the patient. Only the patient using the Program may receive the funds made available through the Program. The Program is not intended for third parties who reduce the amount available to the patient or take a portion for their own purposes. Patients with health plans that redirect Genentech Program assistance intended for patient out-of-pocket costs may be subject to alternate Program benefit structures. Genentech reserves the right to rescind, revoke or amend the Program without notice at any time.
Genentech is committed to helping your patients receive the treatment and medications they need. To this end, we provide a broad range of patient access and assistance programs, including:
Use Priority Review to check if Nutropin AQ is available on formulary. Check off "Priority Review" and complete the fields on the Prescriber Service Form to request this service.
Patient: What other co-pay support options are available to me?
If privately or publicly insured patients have difficulty paying for their Nutropin AQ co-pay, co-insurance, or other expenses, Nutropin GPS can refer them to a co-pay assistance foundation* that supports their disease state. For more information, contact Genentech at 1-866-688-7674.
*Genentech and Nutropin GPS™ do not influence or control the operations or eligibility criteria of any independent co-pay assistance foundation and cannot guarantee co-pay assistance after a referral from Nutropin GPS™. The foundations to which we refer patients are not exhaustive or indicative of Genentech’s or Nutropin GPS™ endorsement or financial support. There may be other foundations to support the patient's disease state.
Patient: I have no insurance or Nutropin is not covered by my plan. Can you help?
The Genentech Patient Foundation gives free Genentech medicine to patients who don’t have insurance coverage or who have financial concerns.
Patients will get free Genentech medicine if they:
Download the Genentech Patient Foundation Enrollment Form to get started with your application. Once completed follow the instructions on where to send the enrollment form.
Once we receive your information, Genentech Patient Foundation will contact you with further instructions. This may include verifying financial eligibility.
CliniicalTrials.gov. A service of the U.S. National Institutes of Health. A Postmarketing Surveillance Program for Nutropin, Nutropin AQ®, and Protropin. Genentech. October 1985-July 2010.
CliniicalTrials.gov. A service of the U.S. National Institutes of Health. A Postmarketing Surveillance Program for Nutropin, Nutropin AQ®, and Protropin. Genentech. October 1985-July 2010.
Nutropin AQ® (somatropin) injection, for subcutaneous use. So. San Francisco, CA: Genentech, Inc; 2016.
Nutropin AQ® (somatropin) injection, for subcutaneous use. So. San Francisco, CA: Genentech, Inc; 2016.
Data on file. Genentech, Inc.
Data on file. Genentech, Inc.
Dook DM, Yuen KCJ, Biller BMK, et al. AACE Guidelines for use of growth hormone in clinical practice. Endocr Pract. 2009;15(Suppl 2), 1-29.
Dook DM, Yuen KCJ, Biller BMK, et al. AACE Guidelines for use of growth hormone in clinical practice. Endocr Pract. 2009;15(Suppl 2), 1-29.
Hokken-Koelega ACS, Saenger P, Cappa M, et al. Unresolved problems concerning optimal therapy of puberty in children with chronic renal diseases. J Pediatric Endocrinol Metab. 2001, Jul;14 Suppl2:945-952.
Hokken-Koelega ACS, Saenger P, Cappa M, et al. Unresolved problems concerning optimal therapy of puberty in children with chronic renal diseases. J Pediatric Endocrinol Metab. 2001, Jul;14 Suppl2:945-952.
Sebastian, a Nutropin patient, and his mom, Andrea, walk through the steps associated with using the NuSpin device for Nutropin therapy.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.